Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.

Authors

Salim K Younis, Jianbo Li, Kristina Dortche, Mohamad Watfa, Rui M Bernardino, Abdulrahman Al-Bayati, Betty Wang, Gagandeep Fervaha, Ruben Olivares, Riccardo Autorino, Jane K Nguyen, Jihad Kaouk, Zeyad R Schwen, Jesse K McKenney, Christopher J Weight

Published in

Urologic oncology. Aug 07, 2026. Epub Aug 07, 2026.

Abstract

Current risk stratification after radical prostatectomy (RP) relies on Grade Group (GG) and genomics, which may not fully capture metastatic potential. Unfavorable histology (UH), defined by adverse architectural patterns such as large cribriform carcinoma and intraductal carcinoma, has emerged as a strong predictor. We evaluated whether integrating genomic and other clinicopathologic variables improves prediction beyond quantitative UH burden.
We analyzed 418 men from an event-enriched RP cohort (1987-2004) with centralized pathology review, Genomic Prostate Score (GPS), and long-term follow-up. We recorded the percentage of tumor with UH (UH%), cribriform size, GG, stage, margin status, prostate-specific antigen, and GPS. Multivariable Cox models and a sequential modeling framework evaluated independent associations and incremental predictive performance for metastasis at 15 years.
During median 15.5-year follow-up, 102 men (24%) developed metastases, all within UH-positive tumors. UH ≥10% was strongly associated with metastasis (hazard ratios [HR] 50.95, 95% confidence intervals [CI] 10.4-249). GPS (HR 1.03 per unit, 95% CI 1.01-1.05) and cribriform size (HR 1.0007 per μm, 95% CI 1.0003-1.0010) were independently associated but added only modest discrimination. UH% alone achieved high 15-year discrimination (c-index ∼0.85); inclusion of GPS and cribriform size increased this to 0.901. Limitations include retrospective design and single-institution pathology review.
UH% is the dominant determinant of metastatic risk after RP, offering greater prognostic discrimination than GG, stage, and other clinicopathologic variables. Genomic classifiers and cribriform size provide secondary refinement but do not materially alter risk once UH burden is established. These findings support pathology-anchored risk models.

PMID:
42567796
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.